Mylan and Theravance Biopharma’s COPD treatment gets FDA approval

world news, trump, u.s., business news, stock market, entertainment news, business news, company news, market, commodities, commodity, Africa news

Nov 9 (Reuters) – Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

The treatment, Yupelri https://www.accessdata.fda.gov/drugsatfdatdocs/label/2018/210598s000lbl.pdf, is once-daily inhalable solution to be used by patients of chronic obstructive pulmonary disease (COPD), a lung disease characterized by wheezing or chronic cough. (Reporting by Manogna Maddipatla in Bengaluru; Editing by Maju Samuel)

Advertisements